Show simple item record

TERIPARATIDE AS TREATMENT OF THE MEDICATION RELATED OSTEONECROSIS OF THE JAWS (MRONJ): A SCOPING REVIEW: TREATMENT OF MRONJ USING TERIPARATIDE

Teriparatide as treatment of the Medication Related Osteonecrosis of the Jaws (MRONJ): a Scoping Review: TREATMENT OF MRONJ USING TERIPARATIDE

dc.creatorBustos Ponce, Alexis Paolo
dc.creatorDethlefs Canto, Jessika
dc.creatorBaeza Vallejos, Solange
dc.creatorVillavicencio Duarte, Javier
dc.creatorHurtado Almonacid, Montserrat
dc.creatorPérez Escobari, Javiera
dc.date2025-07-04
dc.date.accessioned2025-09-23T19:41:38Z
dc.date.available2025-09-23T19:41:38Z
dc.identifierhttps://rhv.uv.cl/index.php/asid/article/view/4642
dc.identifier10.22370/asd.2025.6.1.4642
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/255338
dc.descriptionAbstract Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication affecting patients undergoing therapy with bisphosphonates and other antiresorptive agents. Teriparatide, a parathyroid hormone analog, has emerged as a possible therapeutic option to promote bone regeneration in these cases. This study aims to evaluate the efficacy of teriparatide in the treatment of MRONJ, based on a systematic review of the current literature. Material and methods: An exploratory systematic review was performed following Prisma ScR protocols using the following bibliographic databases Scopus, Pubmed, WOS, ScienceDirect to identify studies between the years 2013 and 2021 that have used teriparatide as a treatment to MRONJ. Results: From a total of 3100 articles, 8 were included in this review.  The following were considered as relevant criteria: initial MRONJ status, dose and time of drug administration and possible adverse effects developed with this therapy.  The studies reviewed reported a significant improvement in bone regeneration and a reduction in MRONJ symptoms in patients treated with teriparatide, highlighting the decrease in bone exposure and showing a favorable safety profile. Conclusions: The findings suggest that teriparatide may be a viable and effective therapeutic option for the treatment of drug-associated osteonecrosis of the jaws. However, the need for further research, particularly long-term clinical trials, to confirm these results and optimize treatment protocols is highlighted.en-US
dc.descriptionIntroduction: Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication affecting patients undergoing therapy with bisphosphonates and other antiresorptive agents. Teriparatide, a parathyroid hormone analog, has emerged as a possible therapeutic option to promote bone regeneration in these cases. This study aims to evaluate the efficacy of teriparatide in the treatment of MRONJ. Material and methods: An exploratory review was performed following Prisma ScR protocols using the following bibliographic databases Scopus, Pubmed, WOS, ScienceDirect to identify studies between the years 2020 and 2024 that have used teriparatide as a treatment to MRONJ. Results: From a total of 3100 articles, 8 were included in this review. The following were considered as relevant criteria: initial MRONJ status, dose and time of drug administration and possible adverse effects developed with this therapy. The studies reviewed reported a significant improvement in bone regeneration and a reduction in MRONJ symptoms in patients treated with teriparatide, highlighting the decrease in bone exposure and showing a favorable safety profile. Discussion: The findings suggest that teriparatide may be a viable and effective therapeutic option for the treatment of drug-associated osteonecrosis of the jaws. However, the need for further research, particularly long-term clinical trials, to confirm these results and optimize treatment protocols is highlighted.es-ES
dc.formatapplication/pdf
dc.languagespa
dc.publisherUniversidad de Valparaísoes-ES
dc.relationhttps://rhv.uv.cl/index.php/asid/article/view/4642/4629
dc.rightsDerechos de autor 2025 Applied Sciences in Dentistryes-ES
dc.rightshttp://creativecommons.org/licenses/by/4.0es-ES
dc.sourceApplied Sciences in Dentistry; Vol. 6 No. 1 (2025); 23-33en-US
dc.sourceApplied Sciences in Dentistry; Vol. 6 Núm. 1 (2025); 23-33es-ES
dc.source0719-5761
dc.source0719-5761
dc.titleTERIPARATIDE AS TREATMENT OF THE MEDICATION RELATED OSTEONECROSIS OF THE JAWS (MRONJ): A SCOPING REVIEW: TREATMENT OF MRONJ USING TERIPARATIDEen-US
dc.titleTeriparatide as treatment of the Medication Related Osteonecrosis of the Jaws (MRONJ): a Scoping Review: TREATMENT OF MRONJ USING TERIPARATIDEes-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record